Key result
Epicardial left atrial appendage exclusion using the AtriClip device achieved a 99.0% successful exclusion rate and a 98.9% stroke-free rate over a mean follow-up of 510 days.
Why the study?
The study aimed to evaluate short- and middle-term results and postoperative anticoagulation of left atrial appendage exclusion using an epicardial clip device.
Does epicardial LAA exclusion using the AtriClip device with 3-month postoperative anticoagulation prevent stroke in patients with atrial fibrillation?
Observational (n=102)
No
Does epicardial LAA exclusion using the AtriClip device with 3-month postoperative anticoagulation prevent stroke in patients with atrial fibrillation?
Epicardial LAA exclusion using the AtriClip device, combined with a 3-month postoperative anticoagulation strategy, is safe and highly effective for stroke prevention in patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
LAA exclusion may yield high stroke-free rates in surgical patients; leaves open confirmation via randomized trials.
OBJECTIVE: The present study aimed to evaluate short- and middle-term results and postoperative anticoagulation of left atrial appendage (LAA) exclusion with an epicardial clip device. MATERIALS AND METHODS: From September 2017 to August 2019, 102 patients at our institution underwent epicardial LAA exclusion using the AtriClip device. Anticoagulation therapy was resumed in the very early postoperative period and continued for at least three months after surgery. The patients' data were obtained by reviewing their medical records retrospectively. RESULTS: The mean and median durations of follow-up was 510 ± 184 days and 482 days (range, 216-938 days), respectively. Successful LAA exclusion was confirmed in all but one patient. No device-related complications occurred during surgery. Postoperative computed tomography (CT) findings revealed no migration or displacement of the clips in any patient; however, small clots were observed at the LAA stump in seven patients. Stroke-free rate during the follow-up period was 98.9%. CONCLUSION: LAA exclusion using the AtriClip device was a feasible treatment method in terms of its early and middle-term safety and efficacy. In addition, our postoperative anticoagulation strategy could be optimal for maximizing the procedure's merits, although further studies, involving a larger number of patients and longer duration of follow-up, are needed.
No takes yet. Share an insight, caveat, or question.
Yoshimoto et al. (2020) conducted an observational in Atrial Fibrillation (n=102). Epicardial left atrial appendage exclusion using the AtriClip device was evaluated on Successful left atrial appendage exclusion. Epicardial left atrial appendage exclusion using the AtriClip device achieved a 99.0% successful exclusion rate and a 98.9% stroke-free rate over a mean follow-up of 510 days.
Synapse has enriched 10 related papers. Consider them for comparative context: